CN105420263B - The production method of recombinant human fibroblast growth factor -17 - Google Patents
The production method of recombinant human fibroblast growth factor -17 Download PDFInfo
- Publication number
- CN105420263B CN105420263B CN201510947022.3A CN201510947022A CN105420263B CN 105420263 B CN105420263 B CN 105420263B CN 201510947022 A CN201510947022 A CN 201510947022A CN 105420263 B CN105420263 B CN 105420263B
- Authority
- CN
- China
- Prior art keywords
- fgf
- albumen
- expression
- growth factor
- fibroblast growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 34
- 101000878124 Homo sapiens Fibroblast growth factor 17 Proteins 0.000 title claims description 56
- 102000057772 human FGF17 Human genes 0.000 title claims description 6
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 claims abstract description 136
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 claims abstract description 87
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 82
- 230000014509 gene expression Effects 0.000 claims abstract description 63
- 241000894006 Bacteria Species 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 239000000243 solution Substances 0.000 claims abstract description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 39
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000011780 sodium chloride Substances 0.000 claims abstract description 36
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims abstract description 31
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims abstract description 31
- 229940126864 fibroblast growth factor Drugs 0.000 claims abstract description 30
- 241000588724 Escherichia coli Species 0.000 claims abstract description 26
- 239000008004 cell lysis buffer Substances 0.000 claims abstract description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims abstract description 10
- 239000013613 expression plasmid Substances 0.000 claims abstract description 9
- 229960001484 edetic acid Drugs 0.000 claims abstract description 8
- 238000003259 recombinant expression Methods 0.000 claims abstract description 8
- 229930006000 Sucrose Natural products 0.000 claims abstract description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 7
- 239000005720 sucrose Substances 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 229940099352 cholate Drugs 0.000 claims abstract description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 6
- 239000003102 growth factor Substances 0.000 claims abstract description 6
- 230000006798 recombination Effects 0.000 claims abstract description 5
- 238000005215 recombination Methods 0.000 claims abstract description 5
- 230000003328 fibroblastic effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 44
- 210000003000 inclusion body Anatomy 0.000 claims description 33
- 239000001963 growth medium Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000012137 tryptone Substances 0.000 claims description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 12
- 229960002897 heparin Drugs 0.000 claims description 12
- 229920000669 heparin Polymers 0.000 claims description 12
- 239000000411 inducer Substances 0.000 claims description 12
- 230000001376 precipitating effect Effects 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 9
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 9
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 9
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000000386 microscopy Methods 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- -1 trihydroxy methyl amino Chemical group 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract description 16
- 239000007983 Tris buffer Substances 0.000 abstract description 10
- 229920004890 Triton X-100 Polymers 0.000 abstract description 10
- 239000013504 Triton X-100 Substances 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 8
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000004153 renaturation Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 101150021185 FGF gene Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000005153 frontal cortex Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012134 supernatant fraction Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101150045940 FGF17 gene Proteins 0.000 description 3
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 description 3
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 description 3
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000003321 cartilage cell Anatomy 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- UYVVLXVBEQAATF-UHFFFAOYSA-N 4-(1,3,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid Chemical compound OC1CC2CC(O)CC(O)C2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 UYVVLXVBEQAATF-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 206010008723 Chondrodystrophy Diseases 0.000 description 2
- 238000007445 Chromatographic isolation Methods 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000008919 achondroplasia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 201000010072 hypochondroplasia Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 201000003896 thanatophoric dysplasia Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101100390682 Rattus norvegicus Fgf17 gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000003861 Ribosomal protein S6 Human genes 0.000 description 1
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000017712 cerebellum development Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960001425 deferoxamine mesylate Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000005690 diesters Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 108700025906 fos Genes Proteins 0.000 description 1
- 101150078861 fos gene Proteins 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a kind of production methods of -17 albumen of recombinant human fibroblast growth factor, at least include the following steps: Step 1: being recombinated and being expanded -17 albumen FGF-17 of human fibroblastic growth factor of native sequences according to Escherichia coli preference；Step 2: the rhFGF-17 gene after recombination is connected to colibacillus expression plasmid, recombinant expression carrier is constituted, recombinant expression carrier conversion is then entered into e. coli host bacteria, obtains FGF-17 protein expression engineering bacteria；And Step 3: to expression engineering bacteria cultivate, purified later；Wherein, in purification process, using the cell lysis buffer solution of following density component: the trishydroxymethylaminomethane Tris of 45-55mM, the sodium chloride nacl of 280~320mM, the sucrose of the ethylenediamine tetra-acetic acid DTA, 0.1~0.3M of 1.5~2.5mM, and the Triton X-100 TritonX-100 that percent by volume is 0.8~1.2%, it is 5%-10% glycerol for 0.1~0.3% deoxysodium cholate, is 0.8~1.2% phenylmethylsulfonyl fluoride PMSF.The concentration and purity is high of the FGF-17 albumen of this production method production.
Description
Technical field
The present invention relates to genetic engineering fields, and in particular to the production method of recombinant human fibroblast growth factor -17.
Background technique
It is a variety of that fibroblast growth factor (Fibroblast Growth Factor, FGF) is that one kind is widely present in
Cell polypeptide growth factor in tissue has now been found that 23 members, and molecular weight is 16kD~34kD, and central area is contained
About 120 amino acid sequences of high homology (30%~70%), to from a variety of of mesoderm and neuroderm
Cell type has extensive biological activity.Content is little but widely distributed in vivo by FGFs, each cytokine regulatory a system
The growth course of column, the differentiation of development, limbs including brain and the formation of trunk.Most of FGFs members and embryonic development, group
Knitting injury repair, the generation of tumour, development and transfer etc. has substantial connection, has considerable application value.
FGF-17 belong to FGF8 subfamily (FGF8, FGF17, FGF18), as other FGF members, belong to paracrine because
Son, and in prostate cancer and liver cancer, FGF17 is also participated in a manner of autocrine.Tissue in embryo development procedure and
It plays an important role in orga- nogenesis.1998, Japanese Scientists Masamitsu Hoshikawa et al. was separated from rat embryo
A kind of cDNA that can encode the FGF17 containing 216 amino acid is obtained, the High for having transfected the baculoviral containing cDNA is utilized
Five insect cell has effectively obtained rat FGF17 albumen.Scientist find FGF17mRAN in rat embryo brain tissue isthmus and
The neural epithelium priority expression of diaphragm.It is most important to illustrate that FGF17 develops fetal brain tissue.Hypotype that there are two types of people FGF17,
FGF17a and b, b are principal mode, the people FGF17 i.e. FGF17b to be expressed in this experiment.People's FGF17 assignment of genes gene mapping is in dye
Colour solid 8p21.3 shares 3 exons, and 6 mutational sites are made of 216 amino acid, with other it has been found that family member
Between with 30%~70% homology, the amino acid sequence of people FGF-17 and mouse has 93% high homology.People
FGF17 molecular weight is about 25kD, and signal peptide has been cut off in this experimental design, only obtains maturation protein partial sequence, finally
Molecular weight of albumen is 22.6kD, and isoelectric point 10.43 is basic protein.In structure, FGF17 is similar to FGF8, FGF18, belongs to same
Family member, homology are respectively 60% and 50%, all have signal peptide sequence, need to be cut using when Bacillus coli expression
It removes.
FGF17 is significant to brain tissue nervous system normal development.FGF17 is the key that brain tissue structure normal development
The factor is expressed and is partly overlapped with the FGF8 of family, and the two is in the region MHB (mid-hindbrain, middle hindbrain) and skin
Matter layer is played an important role.The researchs such as Cholfin discovery FGF17 is the important participation part of frontal cortex cortex subregion, is knocked out
FGF17 will lead to the diminution of back side frontal cortex and frontal cortex projects the reduction of target area degree under cortex；Jingsong
Xu etc. using FGF17 knock-out mice as model find either be born after two days young rat or adult mice, anatomically without
Abnormal and presentation health status, and it is significant to have been found that its midbrain tail end, hypothalamus and vermis of cerebellum occur by histology
Tissue deficient phenomena, i.e. dysplasia.(Hoshikawa et al.Biochem Biophys Res Commun.1998,
244:187–191；Maruoka et al.Mech Dev,1998,74(1-2):175–177；Reifers et al.Mech
Dev,2000,99(1-2):39–49；Cholfin et al.Proc Natl Acad Sci USA,2007,104(18):
7652–7657；Xu J et al.Development,2000,127(9):1833-1843；)
FGF17 has potential value in terms of studying neuropsychiatric disease.For this point, to be related to FGF17 in dyeing
Position on body.It is neuropsychiatry susceptibility loci that a report in 2009, which reviews chromosome 8p, with neuropsychiatric
Disorder (schizophrenia, self-closing disease), neurodegenerative disease (Alzheimer disease, Parkinson), Kallman syndrome etc. are close
Cutting link；8p21-23 is the critical sites of brain agenesis of corpus callus, the latter and cognitive defect, twitch, self-closing disease and spirit
Split disease is closely related.FGF17 gene is located at chromosome 8p 21.3, and hence for studying, above-mentioned illness is significant.Zanni etc.
Case inquires into the relationship of FGF17 Yu cerebellum development and disease to people after study, and in the case, patient sends out with serious growth
Educate slow, epilepsy and DWM (Dandy-Walker malformation, fourth ventricle hole occlusive syndrome, also referred to as non-traffic
Property hydrocephalus) symptom, patient's body chromosome 8p 21.2-p21.3 is away from having deficient phenomena at beginning 2.3Mb for detection discovery, namely
FGF17 gene defect, and analyze patient blood lymphocytes and skin fibroblasts discovery FGF17 expression it is bright
Aobvious to reduce, this is the report for the first time lowered about the small deformity of brain of the mankind and FGF17 genetic transcription；The research such as Scearce-Levie
It was found that FGF17-/-There is exception in mouse social action, shows as the reduction of young rat sounding, adult rats social interaction defect, and find
In human body, the interference of FGF17 signal path may result in a series of Nervous and mental diseases, for example, schizophrenia and from
Close disease, and caused by these abnormal behaviours may be reduced due to the activation of Fos gene in frontal cortex structure that FGF17 is lacked, so
And relevant neural circuitry and signal path mechanism are still known little, it need to be to further probe into.At present for psychoneural side
The disease treatment in face still has insufficient and very large space, hence for studying with very big for the FGF17 gene including being related to
Prospect.(Tabarés-Seisdedos et al.Mol Psychiatry.2009,14(6):563-589；Paul et
al.Nat Rev Neurosci,2007,8(4):287-299；Zanni et al.Neurogenetics,2011,12(3):
241-245；Scearce-Levie et al.Genes Brain Behav,2008,7(3):344-354)
Research of the FGF17 in terms of bone has important value.It is related receptor FGFR3 may to be acted on FGF17.
FGFR3 plays an important role in skeleton development, is the receptor mainly expressed in cartilage cell, and activated mutant will lead to a series of
Skeleton development defective disease, such as achondroplasia (ACH), hypochondroplasia (HCH) and thanatophoric dysplasia
(TD), FGFR3 will lead to nanism in persistent activation osteocyte.Krejci P et al. is detected using ImmunohistochemistryMethods Methods
There is the expression of FGF17 albumen in normal human subject growth plate cartilage, and horizontal consistent with FGF19, then in cell proliferation experiment
It was found that FGF17 and FGF1 peer-level inhibit the chondrocyte proliferation of RCS (rabbit cartilage tumor cartilage cell), as FGF17 is dense
Degree increases, and inhibiting effect is more obvious.When low concentration, FGF17 is proliferated by significantly inhibiting RCS with heparin combination, and individual
FGF17 inhibitory effect is unobvious, and detection discovery FGF17 can lure ERK signal path phosphorylation into.FGF17 is participated in known to
FGFR3 signal path in cartilage cell is activated, lures ERK phosphorylation into, inhibits the growth of cartilage oncocyte, and it is significant to reach
Inhibiting effect needs being used cooperatively for heparin.(Passos-Bueno et al.Hum Mutat,1999,14(2):115-
125；Naski et al.Front.Biosci,1998,3:d781-794；Naski et al.Nat Genet,1996,13
(2):233-237；Shiang et al.Cell,1994,78(2):335-342；Krejci et al.Pediatr Res,
2007,61(3):267-272.)
Influence of the FGF17 for tumorigenesis and transfer.As other fibroblast growth factors, FGF17
It is also a kind of potential carcinogen.FGF17 mainly by tyrosine kinase receptor FGFR3c, FGFR4 with cell surface,
Specific binding (FGFR3c > FGFR4 > FGFR2c > FGFR1c) occurs for FGFR2c and FGFR1c, causes DNA by MAPK approach
Synthesis and promotion cell Proliferation, and when promoting DNA synthesis, the activity of FGF17 induced mitogenesis is twice of FGF8；
The carrier for carrying FGF17a and FGF17b (the main expression-form of people FGF17) gene is transferred to by Jingsong Xu et al.
In NIH3T3 cell, after a week, the cell containing FGF17b 40% occur it is anti-tumor, after fortnight, Suo Youxi
Born of the same parents are completely formed tumour, and the cell containing FGF17a is still at normal condition；Polnaszek and Heer etc. is detected per capita
FGF17 is overexpressed in prostate gland cancer cell, and especially FGF17 expression is higher in DU145 cell line, and Heer etc. is also sent out
FGF17mRNA is in present well differentiated prostate gland cancer cell with the horizontal up-regulation of 4 times of BPH (benign prostatic hyperplasis).
Polnaszek etc. is equal in cancer cell and normal epithelium cell from detecting in the cancer cell of radical-ability prostate removal surgery sample
There is the expression of the FGF17 of similar level (since cancer cell density is big, so in general, FGF17 is inclined in tumor tissue concentration
It is high), expression quantity is relative to FGF7 relatively low (FGF7 28ng/g, FGF17 are 0.4~0.5ng/g)；About breast cancer, at present according to
So prove that FGF17 has expression in breast cancer cell without enough evidences, but Meijer et al. is in tamoxifen treatment cream
Find that the signal transduction of receptor FGFR4 and its ligand FGF17 in tissue cause tamoxifen resistance, this access in gland cancer
The discovery patient invalid for endocrine therapy breast cancer carry out targeted therapy and provide guiding value.Gauglhofer et al.
The expression of FGF8 family of research human liver cancer cell (HCC, the HepG2and Hep3B) discovery including FGF17 is raised,
And this phenomenon may be related with wnt access downward.When hungry or addition simulated hypoxia drug deferoxamine mesylate progress liver cancer is thin
When born of the same parents cultivate, the expression of discovery FGF8 family is dramatically increased, and the liver cancer cells of starvation culture are being added to the FGF8 subfamily factor
Afterwards, Apoptosis is reduced, and this is related with the phosphorylation of ERK1/2 and ribosomal protein S6, when research finds serum-free,
PERK and pS6 is lowered, and pGSK3 β up-regulation, cell survival weakens, and after adding FGF17, pERK up-regulation, liver cancer cells increase.Mesh
Preceding known FGF17 and tumour are closely related, therefore have broad prospects as the target molecule of tumor diagnosis and therapy.
(Zhang X et a.J Biol Chem,2006,281(23):15694–15700；Murray et al.Curr Cancer
Drug Targets,2009,9(5):639–651；Reifers et al.Mech Dev,2000,99(1–2):39–49；Xu J
et al.Mech Dev,1999,83(1-2):165-78；Polnaszek et al.Prostate,2004,60(1):18-24；
Heer et al.J Pathol,2004,204(5):578-586；Meijer et al.Mol Cancer Res,2006,4
(6):379-86；Gauglhofer et al.Hepatology,2011,53(3):854-864.)
Since FGF-17 is for brain tissue, nervous system, bone and tumour etc. important in inhibiting, studies and face
Bed has a extensive future, and is increasingly subject to the concern of scientific research circle.FGF-17 is related both at home and abroad at present as a kind of novel growth factor
It reports fewer.The application patent by the screening of gene optimization, expression vector and host strain, and then obtains Escherichia coli
Efficient expression strain；Optimum culture condition and bacterium solution breaking method are to increase the ratio of soluble protein；Optimize inclusion body washing, become
Property and refolding method, obtain that concentration is higher and the preferable inclusion body protein of purity；Pass through cation exchange column chromatography (HiTrapTM
SP HP), heparin column affinity chromatography (Heparin Sepharose CL-6B), the final purity of protein that obtains is more than 95% and has
The recombined human FGF-17 albumen of higher biological activity, further to carry out FGF-17 dependent interaction Mechanism Study and new drug development
It lays a good foundation.
However, FGF17 protein expression level is low at present, while being difficult the albumen that preparation has high activity.These structures
At the bottleneck problem of FGF18 basic research and clinical application.When producing FGF17 protein expression, generalling use pH value is 7.5
Cell lysis buffer solution, thus temperature when culture leads to final culture purity and concentration not also without strict control
Enough height.
Summary of the invention
The present invention constructs on the basis of early-stage study using colibacillus expression plasmid as the FGF-17 cell table of carrier
Up to system, its cultural method and purification process are mainly improved, and optimize to cultivation temperature.
Therefore, an object of the present invention is to provide a kind of production of -17 albumen of recombinant human fibroblast growth factor
Method solves the problems, such as that FGF-17 protein production concentration and purity are lower；
It is a further object to provide one kind can turn out soluble FGF-17 albumen and inclusion body FGF-17
The method of the albumen of two kinds of forms of albumen.
For this purpose, technical solution provided by the invention are as follows:
A kind of production method of -17 albumen of recombinant human fibroblast growth factor, at least includes the following steps: step
One, -17 albumen FGF-17 of the human fibroblastic growth factor of native sequences is recombinated and is expanded according to Escherichia coli preference
Increase, obtains -17 albumen rhFGF-17 gene of recombinant human fibroblast growth factor, base sequence such as SEQ ID NO:1 institute
Show；
Step 2: the rhFGF-17 gene after recombination is connected to colibacillus expression plasmid, recombinant expression carrier is constituted,
Then recombinant expression carrier conversion is entered into e. coli host bacteria, obtains FGF-17 protein expression engineering bacteria；And
Step 3: cultivating expression engineering bacteria, purified later；
Wherein, in purification process, using the cell lysis buffer solution of following density component: the trihydroxy methyl of 45-55mM
The sodium chloride nacl of aminomethane Tris, 280~320mM, the sugarcane of the ethylenediamine tetra-acetic acid DTA, 0.1~0.3M of 1.5~2.5mM
Triton X-100 TritonX-100 that sugar and percent by volume are 0.8~1.2% goes for 0.1~0.3%
Oxycholic acid sodium is 5%-10% glycerol, is 0.8~1.2% phenylmethylsulfonyl fluoride PMSF；And adjust the cell cracking buffering
The pH value of liquid is between 7.3~7.49.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, described pair of expression
It includes: soluble FGF-17 albumen to be turned out under conditions of 16 DEG C, and cultivate under conditions of 37 DEG C that engineering bacteria, which carries out culture,
Inclusion body FGF-17 albumen out.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, the large intestine bar
Bacterium expression plasmid is pET3a, and the e. coli host bacteria is BL21 (DE3) plysS.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, the cell is split
It solves in buffer, includes: the sodium chloride nacl of the trishydroxymethylaminomethane Tris, 300mM of 50mM, the ethylenediamine tetrem of 2mM
The Triton X-100 TritonX-100 that the sucrose and percent by volume of sour DTA, 0.2M are 1% is 0.2%
Deoxysodium cholate is 5%-10% glycerol, is 1% phenylmethylsulfonyl fluoride PMSF；And adjust the cell lysis buffer solution
PH value is 7.4.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, described pair of expression
Engineering bacteria cultivated the following steps are included:
1) FGF-17 protein expression engineering bacteria is seeded in first generation LB culture medium with the ratio of 1:50~100 and obtains
Generation bacterium；First generation bacterium is cultivated into 8h~12h, to bacteria concentration A600When reaching 1.2~2.0 or so, in the ratio of 1:100~200
It is inoculated into the second generation LB culture medium containing phosphate buffer and is cultivated；
2) it is further cultured for 2h~4h, to bacteria concentration A600When reaching 0.6~0.8 or so, temperature is 15~38 DEG C, inducer
IPTG final concentration of 0.3~0.5mM and 0.8~1.2mM, time are 4~30h, and incubator revolution is 180rpm~200rpm, with
Carry out inducing expression；And
3) centrifugally operated is carried out, obtained FGF-17 albumen is frozen at -15 DEG C or less.
It preferably, can if obtained in the production method of -17 albumen of recombinant human fibroblast growth factor
Dissolubility FGF-17 albumen, then in the step 2), the temperature is 16 DEG C, and the time is 16~30h；And if obtained
Inclusion body FGF-17 albumen, then in the step 2), the temperature is 37 DEG C, and the time is 4~6h.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, in the step
3) in, obtained FGF-17 albumen freezes at -20 DEG C.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, in the step
It 1) include: tryptone 10g/L, yeast powder 5g/L and sodium chloride 10g/L in first generation culture medium in；
It include: tryptone 10g/L, yeast powder in second generation culture medium if obtaining soluble FGF-17 albumen
10g/L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L, sodium chloride 4g/L and glucose 5g/L；And
It include: tryptone 10g/L, yeast powder 4g/ in second generation culture medium if obtaining inclusion body FGF-17 albumen
L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L and sodium chloride 10g/L.
Preferably, in the production method of -17 albumen of recombinant human fibroblast growth factor, forgive in culture
When body FGF-17 albumen, purified using only heparin column, without the use of ion exchange column.
It preferably, can if obtained in the production method of -17 albumen of recombinant human fibroblast growth factor
The cell lysis buffer solution of 25 times of amount g/V is then added in dissolubility FGF-17 albumen, and wherein glycerol is 5% sufficiently suspension, then low temperature
Ultrasonication, wherein power is 300w, and vibration frequency output is 40%；Then ultrasound 5s stops 5s, amounts to ultrasound 10mins；
It after Escherichia coli of the microscopy within the scope of visual fields without intact cell configuration, is centrifuged with 20000rpm, 4 DEG C,
25mins collects supernatant, stays precipitating.
The invention has the benefit that
The present invention is constructed using colibacillus expression plasmid as the FGF-17 e. coli host cell of carrier and is produced
The method of FGF-17 is optimized mainly for the density component of cell lysis buffer solution, and also carries out to cultivation temperature
Optimization, the purity and concentration for eventually leading to product, which obtain, greatly to be improved.
The present invention is also optimized and provides to numerous parameters of incubation and purification process, finally obtains high concentration
With the soluble protein and inclusion body protein of high-purity.
Detailed description of the invention
Fig. 1 is according to the structure chart of the colibacillus expression plasmid PET-3a of one embodiment of the present of invention, wherein lower stroke
It is digestion point at line；
Fig. 2 is according to one embodiment of the present of invention to result after FGF-17 albumen progress inducing expression SDS-PAGE
Electrophoretic analysis figure, wherein appended drawing reference 1 is protein standard substance marker, and appended drawing reference 2-5 is to induce table under conditions of 37 DEG C
It is after reaching as a result, appended drawing reference 6-9 is under conditions of 16 DEG C after inducing expression as a result, appended drawing reference 10 is the knot before induction
Fruit；
Fig. 3 be the expression product obtained at different temperatures according to the FGF-17 albumen of one embodiment of the present of invention can
Dissolubility SDS-PAGE electrophoretic analysis figure, wherein appended drawing reference 1 is protein standard substance marker；Appended drawing reference 2 is the item at 37 DEG C
Result under part after inducing expression；After appended drawing reference 3 is inducing expression under conditions of 37 DEG C, and sink after being crushed when purifying
The result of shallow lake part；Appended drawing reference 4 is the result of supernatant fraction after being crushed under conditions of 37 DEG C；Appended drawing reference 5 is at 37 DEG C
Under conditions of after inducing expression, and it is broken when purifying after supernatant fraction result；Appended drawing reference 6 is under conditions of 16 DEG C
After inducing expression, and it is broken when purifying after sediment fraction result；Appended drawing reference 7 is inducing expression under conditions of 16 DEG C
Result afterwards.
Fig. 4 is according to the inclusion body FGF-17 albuminous degeneration of one embodiment of the present of invention and the SDS-PAGE electrophoresis of renaturation
Analysis chart, wherein appended drawing reference 1 is protein standard substance marker；Appended drawing reference 2 is the supernatant portion by purifying time variation processing
The result divided；Appended drawing reference 3 is the result of the sediment fraction by purifying time variation processing；Appended drawing reference 4 be denaturation after again into
The result of supernatant fraction when row renaturation.
Fig. 5 is to chromatograph SDS-PAGE electrophoretic analysis figure according to the affine heparin column of inclusion body of one embodiment of the present of invention,
Wherein appended drawing reference 1 is protein standard substance marker；Appended drawing reference 2 is to be pierced by the result of affinity column；Appended drawing reference 3-7 is difference
The result of concentration sodium chloride elution；
Fig. 6 be according to one embodiment of the present of invention can the affine heparin column of solution chromatograph SDS-PAGE electrophoretic analysis figure,
Wherein appended drawing reference 1 is protein standard substance marker；Appended drawing reference 2 is the result of supernatant fraction after being crushed when purifying；It is attached
Icon remembers that 3-5 is the result of various concentration sodium chloride elution；
Fig. 7 be according to one embodiment of the present of invention can the affine ion-exchange chromatography SDS-PAGE electrophoretic analysis of solution
Figure, wherein appended drawing reference 1 is protein standard substance marker；Appended drawing reference 2 is the result of affinity column eluting peak；Appended drawing reference 3-5
For the result of various concentration sodium chloride elution；And
Fig. 8 is to measure FGF-17 albumen according to the mtt assay of one embodiment of the present of invention to be proliferated the rush of NIH 3T3 cell
Biological activity figure, wherein topmost the increment of two FGF-17 albumen generations obtained for production method according to the present invention is living
Property, it is far longer than the increment activity of standard items generation.
Specific embodiment
According to the present invention, conventional molecular biological, microbiology, cytology and the DNA weight in the technical ability of this field can be used
Group technology.It is defined as follows if there is in the term that gets off herein.
" DNA molecular " refers to the polymerized form of deoxyribonucleotide (thymidine, cytimidine, adenine or guanine),
It is chromosome main constituents, while is also the material of constitutivegene.This term only refers to the firsts and seconds structure of molecule,
Its any specific three-level form is not limited.This term includes especially in linear DNA molecule, virus, chromosome, plasmid China
It was found that double-stranded DNA.Structure discussed here, according to the sequence in the only direction 5' to 3' of DNA positive-sense strand traditionally provided.
" carrier " is the nucleic acid molecules for referring to transport another nucleic acid connected to it, and a type of carrier is " matter
Grain ", plasmid is that other DNA fragmentations can circular double stranded DNA ring connected to it.Another type of carrier is viral vectors,
Other DNA fragmentations can be connected to viral genome.Certain vector integrations are able to and host into host cell gene group
Genome replicates together.Also, certain carriers can instruct the expression for the gene being operatively connected with it, and what is generally used is such
Expression vector is plasmid form.In the present invention, " plasmid " and " carrier " can be used interchangeably.
" recombinant vector " refers to the expression vector for having had connected gene.In the present invention, it can be used interchangeably " recombinant plasmid "
" recombinant vector ".
Term " host " herein not only includes prokaryotes, also includes that eucaryote such as yeast, plant and animal is thin
Born of the same parents.
" reverse complemental " in the present invention refers to through the associated nucleotide sequence of basepairing rule.For example, sequence " 5 '-
A-T-G-3 ' " and sequence " 5 '-C-A-T-3 ' " reverse complemental.
Primer also known as introduction.It is a bit of single stranded DNA or RNA, as the starting point of DNA replication dna, in nucleic acid synthesis reaction
When, the polynucleotide chain to work as the starting point that each polynucleotide chain is extended, on 3 '-OH of primer, core
Thuja acid is synthesized with diester chain type, therefore 3 '-OH of primer, it is necessary to be free.Why need primer be because
Archaeal dna polymerase can only be added to new nucleotide in existing DNA chain in DNA synthesis.Primer is artificial synthesized two sections
Oligonucleotide sequence, a primer is complementary with a DNA template chain of area-of-interest one end, another primer and region of interest
Another DNA template chain complementation of the domain other end.The chain of the nucleotide sequence of encoded protein amino acid information is carried on DNA
Referred to as positive-sense strand, also known as coding strand.Another chain nucleotide sequences and sense strands complementation, referred to as antisense strand.It generally will be with justice
One primer of chain complementation becomes upstream primer, and a primer complementary with antisense strand is known as downstream primer.
Codon optimization: in gene expression research, researcher pays much attention to the suitable expression vector of selection and host system
Whether system and gene itself are best match with carrier and host system.The optimization expression of gene can be by gene
Redesign and synthesis realize that such as eliminating rare codon and utilizing and optimize codon, secondary structure minimizes, adjustment
G/C content etc..
The present invention is described in further detail with reference to the accompanying drawings and examples, to enable those skilled in the art's reference
Specification word can be implemented accordingly.
The object of the present invention is to provide a kind of methods for easily and efficiently producing FGF-17, including inclusion body and solvable two
Part.
The object of the invention is also to provide carriers or plasmid containing coding FGF-17 gene.
It is a further object of the present invention to provide the expression vectors and host cell for this method.
To achieve the above object, the native sequences of FGF-17 are carried out signal according to Escherichia coli Preference first by the present invention
Peptide excision and codon optimization, design primer pair, wherein upstream primer is as shown in SEQ ID No.2, and downstream primer such as SEQ
Shown in ID No.3.RhFGF-17 sequence is obtained by PCR amplification again.The present invention provides the expression vectors of screening and optimizing simultaneously
With the combination of host cell, pET3a expression vector and corresponding BL21 (DE3) plysS host cell, and by induction when
Between, temperature, the multi-party factor of inducer concentrations grope to compare and construct the bacterial strain of high efficiency stable expression.
Further, the present invention provides a kind of method for producing recombinant human fibroblast growth factor -17, grope 16
The inducing expression of~37 DEG C of albumen carries out broken verifying, finally show that FGF 17 is mainly deposited with inclusion bodies at 37 DEG C
, and considerable 17 albumen of soluble FGF is obtained at 16 DEG C.
Firstly, for body portion is forgiven, by optimizing inclusion body treatment conditions, obtained finally by column chromatographic isolation and purification
High-purity and active rhFGF-17.Specifically comprise the following steps:
(1) engineering bacteria is activated and is expanded by improved seed culture medium, be seeded in 2L fermentation flask and pass through optimization
The high efficient expressions foreign protein such as induction time, inducer concentrations and revolution FGF-17；
(2) optimize cracked solution and bacterial cell disruption is carried out by ultrasonic instrument, low-temperature and high-speed centrifugation abandons and takes back precipitating completely；It is excellent
Change inclusion body cleaning, denaturation and refolding method and step；
(3) it is isolated and purified, is specifically included: cation exchange column chromatography (SP Sepharose Fast by column chromatography
Flow), heparin column chromatography (Heparin Sepharose CL-6B).
Secondly, concrete operations are as follows for soluble protein part:
(1) by improved culture medium ingredient and content, (16 DEG C) of low temperature induce and give inducer concentrations, time and revolution
With optimization；
(2) change lysate ingredient, ultrasonication, low-temperature and high-speed centrifugation obtains the soluble fraction in supernatant；
(3) same to forgive body portion by column chromatographic isolation and purification.
The invention has the following advantages that
(1) it by the combination of the expression vector and host cell that optimize to FGF-17 nucleotide sequence and be suitable for, obtains
Obtain the engineered strain of high efficiency stable expression；
(2) by optimization culture method, the body portion expression of forgiving of FGF-17 can be made to reach bacterial protein
30% or more, soluble fraction reaches 20% of bacterial protein or more；Thallus yield reaches 10g/L fermentation liquid or more；
(3) forgive body portion, expression quantity is high and is crushed and is not easy to be degraded in purification process；It further established inclusion body
Cleaning, denaturation renaturation and column chromatography method, simplify purification step, improve albumen and activity yield, and protein yield reaches 8mg/g
Escherichia coli；Soluble protein part, protein yield reach 1mg/g Escherichia coli；Purity of protein is above 95% or more；
(4) FGF-17 activity determination method is established.Biological activity is reflect recombinant proteins and effect important
Index, the present invention establish the activity determination method that FGF-17 proliferation is carried out with NIH 3T3 cell strain.Experimental result table
Bright FGF17 has apparent rush increment effect to NIH3T3, and reference standard FGF17 albumen, activity is more excellent, compared with blank group, has
Significant difference shows good repeatability and reliability.
The building of 1 FGF-17 albumen efficient expression engineering of embodiment
According to the people FGF17 native sequences (accession number: AY358869.1) and amino acid sequence announced in GenBank, press
It is optimized according to e. coli codon Preference, under conditions of not changing amino acid sequence, designs the coding of rhFGF-17
Aligning primer, and introduce specific cleavage site Nde I and BamH I.The nucleosides of rhFGF-17 is obtained by the method for PCR amplification
Acid sequence, products therefrom are connect for 16 DEG C with carrier T (pEASY T1 simple vector), connection product NdeI and BamHI
The double digestion 4h at 37 DEG C, recycles to obtain rhFGF-17 genetic fragment, then with NdeI and BamHI double digestion with handling and recycle institute
The expression vector pET3a genetic fragment obtained overnight, constructs recombinant expression carrier (see figure with 16 DEG C of Solution I ligase connections
1, Fig. 2).Connection product conversion enters Escherichia coli or BL21 (DE3) plysS, chooses on the LB plate containing carrier resistance
It selects positive colony and carries out plasmid double digestion identification, it was demonstrated that expressed sequence has been correctly inserted into carrier.Entrust gene sequencing company
Carry out positive, Inverse order sequence analysis measurement, it was demonstrated that cloned sequence is completely the same with implementation sequence.Shaking flask culture is carried out, after induction
Measurement destination protein expression quantity accounts for total protein 25% or so, and carries out immunoblotting (Western Blot) detection and the positive is presented instead
It answers, it was demonstrated that expressed recombinant exogenous protein is FGF-17.Engineering bacteria construction test is carried out, continuous passage 50 times, detects it
Plasmid stability, structural stability and expression stability, and confirm to obtain the FGF-17 engineering bacteria of high efficient expression, inheritance stability
Strain is had laid a good foundation for test in next step.Target gene is inserted into the pET of the induction of the operon containing Lac by this engineering bacteria
In serial expression vector, then the e. coli host bacteria compatible with expression vector is converted, carries out inducing expression using IPTG.
The foundation of 2 FGF-17 albumen higher density cultural method of embodiment
In the present invention, with tryptone, yeast powder etc. for nitrogen source, glucose etc. is carbon source, and phosphate is buffer system
Composition, and it is aided with sodium chloride as basic culture medium；And it is aobvious by the adjusting of control condition (pH, temperature, dissolved oxygen, revolution etc.)
Work improves thallus yield and expression.Specifically: FGF-17 engineered strain is seeded in LB culture medium with 1:50~100
First generation bacterium is obtained, 8h~12h is cultivated, to A600Reach 1.2~2.0 or so, is inoculated into the ratio of 1:100~200 containing phosphorus
It is cultivated in the LB culture medium of phthalate buffer, 2h~4h is cultivated, to A600Reach 0.6~0.8 or so, with 16 DEG C of temperature and
37 DEG C, the final concentration of 0.4mM and 1mM of inducer (IPTG), time be respectively 16~30h and 4~6h, incubator revolution 180rpm
~200rpm carries out inducing expression respectively, and low-temperature and high-speed centrifugation, -20 DEG C of thallus freeze, and sample carries out SDS-PAGE detection and surveys
Determine expression quantity (see Fig. 3).
1 culture medium of table composition
The foundation of 3 FGF-17 method for purifying proteins of embodiment
1, the processing of inclusion body
(1) bacterial cell disruption
After thallus multigelation, cell lysis buffer solution (20mM Tris- is suspended in sufficiently with 1:25 (g:mL) ratio
HCl, 1mM EDTA-2Na, 0.2M NaCl, 1%Triton X-100,0.2% deoxysodium cholate, pH7.5), it is super to carry out low temperature
Sound is broken, power 300w, and vibration frequency output 40%, ultrasonic 5s stops 5s, and ultrasonic 10min, microscopy is within the scope of visual fields without complete
After cyto-architectural Escherichia coli, 20000rpm centrifugation 4 DEG C, 25min, abandons supernatant, collects precipitating.
(2) inclusion body cleans
Precipitating after taking above-mentioned centrifugation, be added 20 times of amount washing buffers (20mM Tris-HCl, 1mM EDTA-2Na,
0.2M NaCl, 1%Triton X-100, pH7.5) it is sufficiently stirred washing, after 30min, 20000rpm centrifugation, 4 DEG C, 25min,
Supernatant is abandoned, precipitating is collected.Precipitating is taken again, and 20 times of amount washing buffers (20mM Tris-HCl, 1mM EDTA-2Na, 0.2M are added
NaCl, 1%Triton X-100, pH7.5) it is sufficiently stirred washing, after 30min, 20000rpm centrifugation, 4 DEG C, 25min, in abandoning
Clearly, precipitating is collected, then washed once with washing buffer (20mM Tris-HCl, 0.1M NaCl, pH7.5), inclusion body is obtained.
(3) inclusion body is denaturalized, as shown in Figure 4.
Appropriate inclusion body is weighed, 25 times of amount (g/V) dissolutions buffer (20mM Tris-HCl, 8M urea, pH7.5) are added, fill
Divide and suspend, and room-temperature dissolution is stayed overnight under the conditions of magnetic agitation.20000rpm centrifugation, 4 DEG C, 25min, sediment is abandoned in centrifugation, is obtained
Solubilization of inclusion bodies liquid.
(4) renaturing inclusion bodies, as shown in Figure 4.
Solubilization of inclusion bodies liquid is taken, under the conditions of 4 DEG C of magnetic agitations, first carrying out dialysis urea concentration is 4M, molten after then dialysing
Liquid is slowly dropped into 3 times of volume renaturation buffers (20mM Tris-HCl, pH7.5), until the final concentration of 1M of urea, renaturation process about 12h
~20h.Renaturation finishes, and 20000rpm centrifugation, 4 DEG C, 25min takes supernatant, as renaturation solution.Sample measures protein content, and
Its purity is detected using argentation.
(5) column chromatographic purifying -- affinity chromatography
Chromatography media: Heparin Sepharose CL-6B
Buffer solution: solution I: 20mM Tris-HCl (pH7.0~7.5)+25mM NaCl
Solution II: 20mM Tris-HCl (pH7.0~7.5)+2.0M NaCl
Balance: 3~5 column volumes are balanced with solution A.
Loading: loading after the FGF-17 protein solution desalination that ion-exchange chromatography is collected.
Cleaning: cleaning chromatographic column with the solution I of 3~5 column volumes after loading, until baseline balances.
Gradient: solution B is adjusted to 100% from 0% with 20~30 column volumes after cleaning.
It collects: collecting FGF-17 sample peak, measure protein content, and detect its purity using SDS-PAGE combination silver staining.
Above (see Fig. 5).
2, soluble protein is handled, and sees Fig. 6 and Fig. 7.
(1) bacterial cell disruption
After thallus multigelation, 25 times of amount (g/V) cell lysis buffer solution (20mM Tris, 300mM Nacl are added
1%TritonX-100,1mM EDTA, 0.2% deoxysodium cholate, 5% glycerol, 1%PMSF, PH=7.4) sufficiently suspend, then
Low temperature ultrasonic is broken, power 300w, and vibration frequency output 40%, ultrasonic 5s stops 5s, and ultrasonic 10min, microscopy is within the scope of visual fields
After Escherichia coli without intact cell configuration, 20000rpm centrifugation, collects supernatant, stays precipitating by 4 DEG C, 25min.
(2) washing of precipitate
Will precipitating with 1:10 (g:ml) ratio be suspended in washing buffer (20mM Tris, 300mM Nacl, 1%
TritonX-100,1mM EDTA, 5% glycerol, PH=7.5) be sufficiently stirred washing 30min after, 20000rpm centrifugation, 4 DEG C,
25min collects supernatant.
(3) column chromatographic purifying
A. cation exchange
Chromatography media: SP-Sepharose FF
Buffer solution: solution I: 20mM Tris-HCl (pH7.0~7.5)+25mM NaCl
Solution II: 20mM Tris-HCl (pH7.0~7.5)+2.0M NaCl
Balance: 3~5 column volumes are balanced with solution I.
Loading: by the protein solution loading after renaturation.
Cleaning: cleaning chromatographic column with the solution I of 3~5 column volumes after loading, until baseline balances.
Gradient: solution B is adjusted to 100% from 0% liter with 20~30 column volumes after cleaning.
It collects: collecting FGF-17 sample peak, measure protein content, and detect its purity using SDS-PAGE.
B. affinity chromatography
Same inclusion body.
4 FGF-17 albuminous cell activity test method of embodiment is established
The biological activity of genetic engineering recombinant protein is to reflect the important indicator of drug quality and effect, therefore establish steady
Fixed, sensitive activity determination method is of great significance for the production and quality testing of product, while being also that guidance is clinical and using
The important indicator of pharmaceutical quantities.The present invention promotes epithelium and the mitotic function of interstitial cell according to FGF-17 specificity, uses
Cell proliferation method, selecting mouse embryonic fibroblasts (NIH 3T3 cell) is target cell, in conjunction with MTT colorimetric determination albumen
In vitro biological activity.Experiment shows in starvation media, NIH 3T3 cell slow growth；And add in starvation media
After adding rhFGF-17 albumen, the growth of NIH 3T3 cell is obvious to be accelerated.Use full-automatic microplate reader using 630nm as reference wavelength, in
Absorbance is measured at 570nm.The results show that the FGF-17 albumen of purifying is in about 30ng/ml concentration or so, it is thin to NIH 3T3
Born of the same parents have significant proliferation.Compared with FGF-17 standard items, biological activity is more excellent, no difference of science of statistics (see Fig. 6).
Specifically, the present invention provides a kind of production method of -17 albumen of recombinant human fibroblast growth factor,
It is characterized in that, at least includes the following steps:
Step 1: by -17 albumen FGF-17 of human fibroblastic growth factor of native sequences according to Escherichia coli preference
It is recombinated and is expanded, obtain -17 albumen rhFGF-17 gene of recombinant human fibroblast growth factor, base sequence is such as
Shown in SEQ ID NO:1, and its amino acid sequence is as shown in SEQ ID No.4；
Step 2: the rhFGF-17 gene after recombination is connected to colibacillus expression plasmid, as shown in Figure 1, constituting weight
Then recombinant expression carrier conversion is entered e. coli host bacteria, obtains FGF-17 protein expression engineering bacteria by group expression vector；
And
Step 3: cultivating expression engineering bacteria, purified later；
Wherein, in purification process, using the cell lysis buffer solution of following density component: the trihydroxy methyl of 45-55mM
The sodium chloride nacl of aminomethane Tris, 280~320mM, the sugarcane of the ethylenediamine tetra-acetic acid DTA, 0.1~0.3M of 1.5~2.5mM
Triton X-100 TritonX-100 that sugar and percent by volume are 0.8~1.2% goes for 0.1~0.3%
Oxycholic acid sodium is 5%-10% glycerol, is 0.8~1.2% phenylmethylsulfonyl fluoride PMSF；And adjust the cell cracking buffering
The pH value of liquid is between 7.3~7.49.
Example one: cell lysis buffer solution uses following ingredient:
The sodium chloride nacl of the trishydroxymethylaminomethane Tris, 280mM of 45mM, the ethylenediamine tetra-acetic acid DTA of 1.5mM,
The Triton X-100 TritonX-100 that the sucrose and percent by volume of 0.1M is 0.8% is 0.1% deoxidation
Sodium taurocholate is 5% glycerol, is 0.8% phenylmethylsulfonyl fluoride PMSF.PH value is adjusted to 7.45:
Experiments have shown that the FGF-17 protein active purified are as follows:
| Concentration ng/ml | Active OD600 |
| 250 | 0.733 |
| 62.5 | 0.713 |
| 15.625 | 0.675 |
Counter-example one: cell lysis buffer solution uses following ingredient:
20mM Tris-HCl, 1mM EDTA-2Na, 0.2M NaCl, 1%Triton X-100,0.2% deoxysodium cholate,
pH7.5.PH value is adjusted to 7.5, remaining situation is identical.
Experiments have shown that the FGF-17 protein active purified are as follows:
| Concentration ng/ml | Active OD600 |
| 250 | 0.621 |
| 62.5 | 0.601 |
| 15.625 | 0.538 |
It has been found that the component and pH value of cell lysis buffer solution are very big to final activity influence.
Example two: cell lysis buffer solution uses following ingredient:
The sodium chloride nacl of the trishydroxymethylaminomethane Tris, 320mM of 55mM, the ethylenediamine tetra-acetic acid DTA of 2.5mM,
The Triton X-100 TritonX-100 that the sucrose and percent by volume of 0.3M is 1.2% is 0.3% deoxidation
Sodium taurocholate is 10% glycerol, is 1.2% phenylmethylsulfonyl fluoride PMSF.PH value is adjusted to 7.3:
Experiments have shown that the FGF-17 protein active purified are as follows:
Example three: cell lysis buffer solution uses following ingredient:
The sodium chloride nacl of the trishydroxymethylaminomethane Tris, 300mM of 50mM, the ethylenediamine tetra-acetic acid DTA of 2mM,
The Triton X-100 TritonX-100 that the sucrose and percent by volume of 0.2M is 1% is 0.2% deoxidation gallbladder
Sour sodium is 7.5% glycerol, is 1% phenylmethylsulfonyl fluoride PMSF.PH value is adjusted to 7.4:
Experiments have shown that the FGF-17 protein active purified are as follows:
| Concentration ng/ml | Active OD600 |
| 250 | 0.774 |
| 62.5 | 0.730 |
| 15.625 | 0.711 |
Also, the FGF-17 albumen come is turned out through the invention, bioactivity is higher than the egg grown naturally in human body
It is white, specifically see Fig. 8.In fig. 8, from bottom to top Article 2 line be nature growth albumen, and Article 3 and Article 4 are these
The FGF-17 albumen come is turned out in invention, it is clear that albumen of its activity much higher than nature growth.
One of situation is, described in the production method of -17 albumen of recombinant human fibroblast growth factor
Carrying out culture to expression engineering bacteria includes: that soluble FGF-17 albumen is turned out under conditions of 16 DEG C, and in 37 DEG C of condition
Under turn out inclusion body FGF-17 albumen, as shown in Figure 3.
This temperature condition is quite important, is the conclusion that comes out of the applicant by many experiments, specifically see following
Experimental result:
Example four:
Experiments have shown that the activity of the FGF-17 albumen purified is (wherein by taking concentration is 30ng/ml as an example, to live at this time
Property highest):
Above-mentioned test is and the experiment done in the identical situation of remaining condition except temperature is different.
In the production method of -17 albumen of recombinant human fibroblast growth factor, the Bacillus coli expression matter
Grain is pET3a, as shown in Figure 1, wherein showing the position of double enzyme cuttings, and the e. coli host bacteria is BL21 (DE3)
plysS。
In the production method of -17 albumen of recombinant human fibroblast growth factor, the cell lysis buffer solution
In, include: the sodium chloride nacl of the trishydroxymethylaminomethane Tris, 300mM of 50mM, the ethylenediamine tetra-acetic acid DTA of 2mM,
The Triton X-100 TritonX-100 that the sucrose and percent by volume of 0.2M is 1% is 0.2% deoxidation gallbladder
Sour sodium is 5%-10% glycerol, is 1% phenylmethylsulfonyl fluoride PMSF；And the pH value for adjusting the cell lysis buffer solution is
7.4。
In the production method of -17 albumen of recombinant human fibroblast growth factor, described pair of expression engineering bacteria into
Row culture the following steps are included:
1) FGF-17 protein expression engineering bacteria is seeded in first generation LB culture medium with the ratio of 1:50~100 and obtains
Generation bacterium；First generation bacterium is cultivated into 8h~12h, to bacteria concentration A600When reaching 1.2~2.0 or so, in the ratio of 1:100~200
It is inoculated into the second generation LB culture medium containing phosphate buffer and is cultivated；
2) it is further cultured for 2h~4h, to bacteria concentration A600When reaching 0.6~0.8 or so, temperature is 15~38 DEG C, inducer
IPTG final concentration of 0.3~0.5mM and 0.8~1.2mM, time are 4~30h, and incubator revolution is 180rpm~200rpm, with
Inducing expression is carried out, as shown in Figure 2；And
3) centrifugally operated is carried out, obtained FGF-17 albumen is frozen at -15 DEG C or less.
Example five: incubation uses following parameter:
FGF-17 protein expression engineering bacteria is seeded in first generation LB culture medium with the ratio of 1:100 and obtains the first generation
Bacterium；First generation bacterium is cultivated into 12h, to bacteria concentration A600When reaching 2.0 or so, it is inoculated into the ratio of 1:200 slow containing phosphate
It is cultivated in the second generation LB culture medium of fliud flushing；
2) it is further cultured for 4h, to bacteria concentration A600When reaching 0.8 or so, temperature is 37 DEG C, and inducer IPTG is final concentration of
0.5mM and 1.2mM, time 30h, incubator revolution is 200rpm, to carry out inducing expression；And
3) centrifugally operated is carried out, obtained FGF-17 albumen is frozen at -20 DEG C.
Experiments have shown that the FGF-17 protein active purified are as follows:
In above-mentioned parameter, the combination configuration of time and concentration is very crucial, if changing other configurations, experimental result is such as
Under:
Counter-example two: incubation uses following parameter:
FGF-17 protein expression engineering bacteria is seeded in first generation LB culture medium with the ratio of 1:130 and obtains the first generation
Bacterium；First generation bacterium is cultivated into 20h (transition culture, unfavorable to second generation culture), to bacteria concentration A600When reaching 4.0 or so, by 1:
200 ratio is inoculated into the second generation LB culture medium containing phosphate buffer and is cultivated；
2) it is further cultured for 2h, to bacteria concentration A600When reaching 0.8 or so, temperature is 40 DEG C, and inducer IPTG is final concentration of
0.5mM and 1.2mM, time 30h, incubator revolution is 200rpm, to carry out inducing expression；And
3) centrifugally operated is carried out, obtained FGF-17 albumen is frozen at -20 DEG C.
Experiments have shown that the FGF-17 protein active purified are as follows:
| Concentration ng/ml | Active OD600 |
| 250 | 0.558 |
| 62.5 | 0.603 |
| 15.625 | 0.572 |
As it can be seen that if the parameter of modification first time and second this culture, can generate adverse consequences.
In the production method of -17 albumen of recombinant human fibroblast growth factor, if obtaining soluble FGF-
17 albumen, then in the step 2), the temperature is 16 DEG C, and the time is 16~30h；And if obtaining inclusion body
FGF-17 albumen, then in the step 2), the temperature is 37 DEG C, and the time is 4~6h.
The combination of temperature and time and the discovery of the applicant, which determine the solubility of albumen.
The production method of -17 albumen of recombinant human fibroblast growth factor obtains in the step 3)
FGF-17 albumen freezes at -20 DEG C.
The production method of -17 albumen of recombinant human fibroblast growth factor, in the step 1),
It include: tryptone 10g/L, yeast powder 5g/L and sodium chloride 10g/L in first generation culture medium；
It include: tryptone 10g/L, yeast powder in second generation culture medium if obtaining soluble FGF-17 albumen
10g/L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L, sodium chloride 4g/L and glucose 5g/L；And
It include: tryptone 10g/L, yeast powder 4g/ in second generation culture medium if obtaining inclusion body FGF-17 albumen
L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L and sodium chloride 10g/L.
Example six: incubation uses following culture medium:
It include: tryptone 10g/L, yeast powder 5g/L and sodium chloride 10g/L in first generation culture medium；
It include: tryptone 10g/L, yeast powder in second generation culture medium if obtaining soluble FGF-17 albumen
10g/L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L, sodium chloride 4g/L and glucose 5g/L；And
It include: tryptone 10g/L, yeast powder 4g/ in second generation culture medium if obtaining inclusion body FGF-17 albumen
L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L and sodium chloride 10g/L.
Experiments have shown that the FGF-17 protein active purified are as follows:
| Concentration ng/ml | Active OD600 |
| 1.953 | 0.561 (can solution), 0.571 (inclusion body) |
| 3.906 | 0.603 (can solution), 0.597 (inclusion body) |
| 31.25 | 0.652 (can solution), 0.665 (inclusion body) |
In above-mentioned parameter, the combination configuration of time and concentration is very crucial, if changing other configurations, experimental result is such as
Under:
Counter-example three: incubation uses following culture medium:
It include: tryptone 13g/L, yeast powder 8g/L and sodium chloride 5g/L in first generation culture medium；
It include: tryptone 13g/L, yeast powder 7g/L, dipotassium hydrogen phosphate 6g/L, potassium dihydrogen phosphate in second generation culture medium
3g/L, sodium chloride 8g/L and glucose 10g/L；
Experiments have shown that in the case where remaining condition is constant, the FGF-17 protein active that purifies are as follows:
| Concentration ng/ml | Active OD600 |
| 1.953 | 0.505 |
| 3.906 | 0.574 |
| 31.25 | 0.532 |
In the production method of -17 albumen of recombinant human fibroblast growth factor, in culture inclusion body FGF-17
It when albumen, is purified using only heparin column, without the use of ion exchange column.As shown in Figure 5.Be not only able in this way save at
This, moreover it is possible to obtain better purification effect.
The production method of -17 albumen of recombinant human fibroblast growth factor, if obtaining soluble FGF-17
The cell lysis buffer solution of 25 times of amount g/V is then added in albumen, and wherein glycerol is 5% sufficiently suspension, and then low temperature ultrasonic is broken,
Wherein power is 300w, and vibration frequency output is 40%；Then ultrasound 5s stops 5s, amounts to ultrasound 10mins；
It after Escherichia coli of the microscopy within the scope of visual fields without intact cell configuration, is centrifuged with 20000rpm, 4 DEG C,
25mins collects supernatant, stays precipitating.
This is the unique processing mode of soluble protein, is characterized by intermittent ultrasound, i.e. ultrasound 5s stops 5s, is amounted to super
Sound 10mins.It can be improved the activity of albumen after purification in this way.
Claims (4)
1. a kind of production method of -17 albumen of recombinant human fibroblast growth factor, which is characterized in that include at least following step
It is rapid:
Step 1: by (hFGF-17) gene of human fibroblastic growth factor -17 of native sequences according to Escherichia coli preference into
Row recombination and amplification, obtain recombinant human fibroblast growth factor -17 (rhFGF-17) gene, base sequence such as SEQID
Shown in No.1；
Step 2: the rhFGF-17 gene after recombination is connected to colibacillus expression plasmid, recombinant expression carrier is constituted, then
Recombinant expression carrier conversion is entered into e. coli host bacteria, obtains FGF-17 protein expression engineering bacteria；And
Step 3: cultivating expression engineering bacteria, purified later；
Wherein, in purification process, break process is carried out to thallus, comprising: after thallus multigelation, with 1g:25mL ratio
It is sufficiently suspended in cell lysis buffer solution, low temperature ultrasonic is carried out and is crushed, power 300w, vibration frequency output 40%, ultrasonic 5s stops 5s, surpasses
Sound, which is crushed, amounts to 10min, after Escherichia coli of the microscopy within the scope of visual fields without intact cell configuration, 20000rpm centrifugation, and 4
DEG C, 25min collects supernatant, precipitating is stayed, using the cell lysis buffer solution of following density component: the trihydroxy methyl amino of 50mM
Methane, the sodium chloride of 300mM, the ethylenediamine tetra-acetic acid of 2mM, the polyethylene glycol that the sucrose and percent by volume of 0.2M is 1%
Octyl phenyl ether, the deoxysodium cholate that percent by volume is 0.2%, percent by volume are 5%-10% glycerol, percent by volume
For 1% phenylmethylsulfonyl fluoride；And
The pH value for adjusting the cell lysis buffer solution is 7.4；
Described pair of expression engineering bacteria cultivated the following steps are included:
FGF-17 protein expression engineered strain is seeded in first generation culture medium with the ratio of 1:50~100 and obtains by step 1)
First generation bacterium；First generation bacterium is cultivated into 8h~12h, to bacteria concentration A600When reaching 1.2~2.0 or so, by the ratio of 1:100~200
Example, which is inoculated into the second generation culture medium containing phosphate buffer, is cultivated；
Step 2), culture 2h~4h, to bacteria concentration A600When reaching 0.6~0.8, it is divided into two parts difference inducing expression:
First part is under conditions of temperature is 16 DEG C, the final concentration of 0.4mM of inducer IPTG, and the time is 16~30h；
Second part is under conditions of temperature is 37 DEG C, the final concentration of 1mM of inducer IPTG, and the time is 4~6h；Incubator revolution
It is 180rpm~200rpm；And
Step 3) carries out centrifugally operated, and obtained thallus is frozen at -15 DEG C or less；
In the step 1),
It include: tryptone 10g/L, yeast powder 5g/L and sodium chloride 10g/L in first generation culture medium；
When condition of culture is the final concentration of 0.4mM of inducer IPTG under conditions of temperature is 16 DEG C, the time is 16~30h, second
For including: tryptone 10g/L, yeast powder 4g/L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L and sodium chloride in culture medium
10g/L；Or
When condition of culture is the final concentration of 1mM of inducer IPTG under conditions of temperature is 37 DEG C, the time is 4~6h, and second is commissioned to train
Supporting in base includes: tryptone 10g/L, yeast powder 10g/L, dipotassium hydrogen phosphate 3g/L, potassium dihydrogen phosphate 1g/L, sodium chloride 4g/L
With glucose 5g/L；
Wherein, the colibacillus expression plasmid is pET3a, and the e. coli host bacteria is BL21 (DE3) plysS.
2. the production method of -17 albumen of recombinant human fibroblast growth factor as described in claim 1, which is characterized in that
It includes: that soluble FGF-17 protein expression engineering bacteria is turned out under conditions of 16 DEG C that described pair of expression engineering bacteria, which carries out culture,
And inclusion body FGF-17 protein expression engineering bacteria is turned out under conditions of 37 DEG C.
3. the production method of -17 albumen of recombinant human fibroblast growth factor as described in claim 1, which is characterized in that
In the step 3), obtained thallus freezes at -20 DEG C.
4. the production method of -17 albumen of recombinant human fibroblast growth factor as claimed in claim 2, which is characterized in that
When purifying inclusion body FGF-17 albumen, purified using only heparin column, without the use of ion exchange column.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510947022.3A CN105420263B (en) | 2015-12-16 | 2015-12-16 | The production method of recombinant human fibroblast growth factor -17 |
| PCT/CN2016/075747 WO2017101221A1 (en) | 2015-12-16 | 2016-03-07 | Method for producing recombinant human fibroblast growth factor-17 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510947022.3A CN105420263B (en) | 2015-12-16 | 2015-12-16 | The production method of recombinant human fibroblast growth factor -17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105420263A CN105420263A (en) | 2016-03-23 |
| CN105420263B true CN105420263B (en) | 2019-07-26 |
Family
ID=55498804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510947022.3A Expired - Fee Related CN105420263B (en) | 2015-12-16 | 2015-12-16 | The production method of recombinant human fibroblast growth factor -17 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105420263B (en) |
| WO (1) | WO2017101221A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107383182A (en) * | 2017-04-11 | 2017-11-24 | 温州医科大学 | The rhFGF7 albumen of Bacillus coli expression and application |
| CN107012150A (en) * | 2017-05-12 | 2017-08-04 | 温州医科大学 | The assay method of the clone of recombinant human fibroblast growth factor 16, expression and application and its biological activity |
| CN107217069B (en) * | 2017-05-31 | 2020-06-26 | 何伟 | Prokaryotic expression vector, rbFGF-2 expression method, engineering bacteria and application |
| CN111100795A (en) * | 2019-12-27 | 2020-05-05 | 深圳康泰生物制品股份有限公司 | Recombinant hansenula polymorpha cell disruption buffer solution for expressing hand-foot-and-mouth disease vaccine antigen and preparation method and application thereof |
| CN111411138A (en) * | 2020-03-27 | 2020-07-14 | 苏州佑宁康生物技术有限公司 | Preparation method of recombinant protein |
| CN116621968B (en) * | 2023-07-21 | 2023-09-22 | 江苏亨瑞生物医药科技有限公司 | Purification method of recombinant III type humanized collagen |
| CN117838835A (en) * | 2024-02-01 | 2024-04-09 | 暨南大学 | Application of fibroblast growth factor 17 protein and/or activator thereof in preparation of medicine for treating Alzheimer disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104293821A (en) * | 2014-08-13 | 2015-01-21 | 温州医科大学 | Gene cloning, expression and application of recombinant human fibroblast growth factor-20 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100484653B1 (en) * | 2004-05-06 | 2005-04-20 | 주식회사 대웅 | Preparation method for the production of active and soluble proteins in prokaryotes and polycistronic vectors therefor |
| CN100562576C (en) * | 2008-09-28 | 2009-11-25 | 李校堃 | The production method of a kind of secretion expression recombinant human fibroblast growth factor-21 |
| CN102206278B (en) * | 2011-05-06 | 2013-04-17 | 中国海洋大学 | Monoclonal antibody of anti-LCDV (lymphocystis disease virus) 27.8kDa receptor protein and preparation method thereof |
| CN103305522B (en) * | 2013-06-20 | 2015-11-25 | 江苏省原子医学研究所 | A kind of nucleotide sequence of optimum combination Human Ciliary Neurotrophic Factor and in intestinal bacteria solution expression with high efficiency method |
-
2015
- 2015-12-16 CN CN201510947022.3A patent/CN105420263B/en not_active Expired - Fee Related
-
2016
- 2016-03-07 WO PCT/CN2016/075747 patent/WO2017101221A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104293821A (en) * | 2014-08-13 | 2015-01-21 | 温州医科大学 | Gene cloning, expression and application of recombinant human fibroblast growth factor-20 |
Non-Patent Citations (3)
| Title |
|---|
| AY358869.1;Clark H.F.;《Genbank》;20031003;序列 |
| FGF17在大肠杆菌中的表达及其生物作用的研究;吴美玉 等;《中国生物工程学会2014年学术年会暨全国生物技术大会》;20141107;1-2 |
| HaloTag is an effective expression and solubilisation fusion partner for a range of fibroblast growth factors;Sun Changye等;《PEERJ》;20150625;第3卷;e1060 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105420263A (en) | 2016-03-23 |
| WO2017101221A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105420263B (en) | The production method of recombinant human fibroblast growth factor -17 | |
| Murakami et al. | Epidermal LysM receptor ensures robust symbiotic signalling in Lotus japonicus | |
| CN106701823A (en) | Establishment and application of CHO cell line for producing fucose-free monoclonal antibody | |
| US7250275B2 (en) | Nucleic acid encoding chicken leukemia inhibitory factor (LIF) | |
| CN105950541B (en) | A kind of construction method of hFGF21 gene knockout human liver cell strain | |
| HU196237B (en) | Process for producing human growth prehormone | |
| CN107109370A (en) | The recombinant glycoprotein of O glycan sialylations and for producing its cell line | |
| CN107955067B (en) | Two MYB transcription factors involved in peach flavonol biosynthesis regulation and control and application thereof | |
| CN104293821A (en) | Gene cloning, expression and application of recombinant human fibroblast growth factor-20 | |
| Ihara et al. | Involvement of the α-helical and Src homology 3 domains in the molecular assembly and enzymatic activity of human α1, 6-fucosyltransferase, FUT8 | |
| CN109312329A (en) | Improve the molecular complex that the mutation in genome sequence modification technique imports the method for efficiency and its uses | |
| CN102453716A (en) | Clone and application of pig skeletal muscle specificity expression gene alpha-actin promoters | |
| CN105176908B (en) | A kind of production method of recombinant human fibroblast growth factor (FGF) -18 | |
| CN114107299B (en) | sgRNA for targeted knockout of duck cGAS gene and application thereof | |
| CN111254130A (en) | Method for inhibiting tumor growth by DDX24 helicase point mutation and application thereof | |
| CN102898514A (en) | Recombinant human nerve growth factor deletion mutant, its preparation method and application | |
| CN114807384A (en) | SNP molecular marker related to chicken carcass traits and application thereof | |
| CN101541959A (en) | Matrix attachment regions (MARs) for increasing transcription and uses thereof | |
| Darabi et al. | Codon optimization, cloning and expression of the human Leukemia Inhibitory Factor (hLIF) in E. coli | |
| CN107012150A (en) | The assay method of the clone of recombinant human fibroblast growth factor 16, expression and application and its biological activity | |
| CN104109669A (en) | SNP in promoter region of pig AMPD1 gene as genetic marker of pig carcass characteristics and applications thereof | |
| CN102747082B (en) | Pig muscle-specific ITGB1BP2 promoter and application thereof | |
| CN106801060B (en) | Gene clone, expression and application of recombinant human fibroblast growth factor-22 | |
| CN110257340A (en) | CHO cell line of Dnmt3b gene defection type and preparation method thereof, application, recombinant protein expression system | |
| JP2006304642A (en) | Transgenic mouse for measuring expression levels of two clock genes by using luciferase activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ma Jisheng Inventor after: Jiang Chao Inventor after: Tian Haishan Inventor after: Liu Min Inventor after: Wu Meiyu Inventor before: Jiang Chao Inventor before: Ma Jisheng Inventor before: Tian Haishan Inventor before: Liu Min Inventor before: Wu Meiyu |
|
| CB03 | Change of inventor or designer information | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190726 Termination date: 20211216 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |